Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Improved outcomes in PTCL with the use of novel agents and transplantation

Jia Ruan • 31 Jan 2019
ASH 2018
Lymphoma Non-Hodgkin Lymphoma T-Cell Lymphoma

Jia Ruan, MD, PhD, of Weill Cornell Medical College, New York, NY, discusses the results of a retrospective study investigating the treatment outcomes of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). Speaking at the 2018 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA, Dr Ruan explains that novel agents did not impact the overall survival of these patients, but goes on to say that patients who then underwent stem cell transplantation had improved survival outcomes. Further research in the area is needed to answer questions more definitively.

More from Jia Ruan

5:12
Phase II trial of acalabrutinib, lenalidomide and rituximab in patients with MCL
Jia Ruan • 10 Dec 2022
6:56
Emerging therapies in MCL: the promise of immunotherapies
Jia Ruan • 4 Oct 2022
3:53
Treatment approaches for older patients with MCL
Jia Ruan • 4 Oct 2022
5:41
Azacitidine and CHOP in PTCL
Jia Ruan • 26 Nov 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals